Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03072043 · OUTCOME

Phase 2: Duration of Response

Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms · Source last updated 2022-01-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
Full Range
Time frame
Up to 24 months

What was measured

Duration of response defined as the time between achieving response and progression of disease.

Analysis population: 45 participants were evaluable for response.

Groups in this outcome

Evaluable Participants

All evaluable participants

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Evaluable Participants45

Reported measurements

Source class 1
Values in months · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Evaluable Participants8Not reported6.511.2Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        6.5
        upper Limit
        11.2
        value
        8
denoms
  1. counts
    1. group Id
      OG000
      value
      45
    units
    Participants
description
Duration of response defined as the time between achieving response and progression of disease.
dispersion Type
Full Range
groups
  1. description
    All evaluable participants
    id
    OG000
    title
    Evaluable Participants
param Type
MEDIAN
population Description
45 participants were evaluable for response.
reporting Status
POSTED
time Frame
Up to 24 months
title
Phase 2: Duration of Response
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice